X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.2217
-0.0147 (-6.22%)
At close: Apr 1, 2025, 4:00 PM
0.2210
-0.0007 (-0.32%)
After-hours: Apr 1, 2025, 4:36 PM EDT

Company Description

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.

It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.

It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand.

The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 143
CEO Paula Ragan

Contact Details

Address:
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
United States
Phone 857 529 8300
Website x4pharma.com

Stock Details

Ticker Symbol XFOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501697
CUSIP Number 98420X103
ISIN Number US98420X1037
Employer ID 27-3181608
SIC Code 2836

Key Executives

Name Position
Adam S. Mostafa Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. Chief Medical Officer
Dr. Richard Peters M.D., Ph.D. Chairman of the Board and Founder
Dr. Renato T. Skerlj Ph.D. Founder
Dr. Keith T. Flaherty M.D. Founder and Member of Corporate Advisory Board
Dr. Mary DiBiase Ph.D. Chief Operating Officer
Dr. Arthur Taveras Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 26, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 24, 2025 DEF 14A Other definitive proxy statements
Mar 14, 2025 PRE 14A Other preliminary proxy statements
Mar 3, 2025 8-K Current Report
Feb 6, 2025 8-K Current Report
Jan 31, 2025 SCHEDULE 13G/A Filing
Jan 24, 2025 144 Filing
Jan 24, 2025 144 Filing